Novo Nordisk (NOV:N) has presented promising data both on a Phase III drug and an existing product at the Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.
The Danish company, a giant in the diabetes field, has seen its share price go up by almost 5% this week, as Novo Nordisk bosses and study investigators have revealed the latest findings on semaglutide and Victoza (liraglutide).
Semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, which has completed six Phase IIIa clinical trials for the treatment of adults with type 2 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze